Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large growth in short interest in September. As of September 15th, there was short interest totalling 6,400 shares, a growth of 25.5% from the August 31st total of 5,100 shares. Currently, 0.2% of the shares of the stock are short sold. Based on an average trading volume of 12,200 shares, the days-to-cover ratio is presently 0.5 days.

Pulmatrix Stock Performance

PULM traded up $0.11 during midday trading on Friday, hitting $2.14. The company had a trading volume of 5,541 shares, compared to its average volume of 10,141. The company has a market capitalization of $7.81 million, a PE ratio of -0.89 and a beta of 0.99. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $2.75. The firm’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $1.98.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The business had revenue of $1.55 million for the quarter.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Pulmatrix in a research report on Monday, September 23rd. They issued a “hold” rating for the company.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.